Literature DB >> 12236924

[Permanent atrial fibrillation in heart disease in Spain. The CARDIOTENS study 1999].

José María García-Acuña1, José Ramón González-Juanatey, Eduardo Alegría Ezquerra, Isidoro González Maqueda, José Luis Listerri.   

Abstract

INTRODUCTION AND
OBJECTIVE: Atrial fibrillation is the most common arrhythmia seen in clinical practice. The objective of this study was to know the frequency of atrial fibrillation and the characteristics of patients with atrial fibrillation in the Cardiotens study. MATERIAL AND
METHOD: A cross-section study with systematic selection of the study sample. All 32,051 outpatients seen on the same day by 1,159 physicians specialized in primary-care (79%) and cardiology (21%) were prospectively added to a database including history of cardiac disease (heart failure, coronary disease or atrial fibrillation), blood pressure, and ongoing treatment.
RESULTS: Atrial fibrillation was present in 25% of patients with previous cardiovascular disease (6,194 patients), the prevalence being 4.8% (1,540/32,051) of the study population. Atrial fibrillation was more frequent in females 29%, (810/2,837) than in males, 22% (730/3,367), p < 0.005). Atrial fibrillation was present in 33% (469/1,420) of patients with heart failure and in 12% (387/3,226) of those with coronary heart disease. Arterial hypertension was diagnosed in 25% of the patients with atrial fibrillation. Only 33% of them were treated with oral anticoagulants (41% of the patients seen by cardiologists and 26% by primary-care physicians, p < 0.005). The antiarrhythmic drug most often used was digoxin (36%).
CONCLUSIONS: Atrial fibrillation had the same frequency and epidemiology in Spain as in other Western countries. Antithrombotic therapy is underused by primary-care physicians and cardiologists.

Entities:  

Mesh:

Year:  2002        PMID: 12236924

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  8 in total

1.  Heart failure in patients with preserved and deteriorated left ventricular ejection fraction.

Authors:  A Varela-Roman; L Grigorian; E Barge; P Bassante; M G de la Peña; J R Gonzalez-Juanatey
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

Review 2.  Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.

Authors:  Antoni Martínez-Rubio; Mario DiazNuila Alcazar; Anna Soria Cadena; Roger Martínez-Torrecilla
Journal:  Eur Cardiol       Date:  2016-12

Review 3.  Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive Drugs.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  J Atr Fibrillation       Date:  2011-12-20

4.  Predictors of incident atrial fibrillation and influence of medications: a retrospective case-control study.

Authors:  James A Hodgkinson; Clare J Taylor; F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

5.  Improvement in the Management of Oral Anticoagulation in Patients with Atrial Fibrillation in Primary Health Care.

Authors:  África García-Roy; Ana Sarsa-Gómez; Fátima Méndez-López; Blanca Urdin-Muñoz; María Antonia Sánchez-Calavera
Journal:  Int J Environ Res Public Health       Date:  2022-05-31       Impact factor: 4.614

6.  Gender differences related to the presence of atrial fibrillation in older hypertensive patients.

Authors:  Lorenzo Fácila; Vicente Pallarés; Pedro Morillas; Alberto Cordero; Jose Luis Llisterri; Carlos Sánchis; Jose L Gorriz; Jesus Castillo; Vicente Gil; Josep Redon
Journal:  World J Cardiol       Date:  2013-05-26

7.  Direct vitamin K antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation.

Authors:  Álvaro Hidalgo-Vega; Elham Askari; Rosa Vidal; Isaac Aranda-Reneo; Almudena Gonzalez-Dominguez; Alexandra Ivanova; Gabriela Ene; Pilar Llamas
Journal:  BMC Health Serv Res       Date:  2014-01-30       Impact factor: 2.655

8.  [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].

Authors:  Ginés Escolar-Albaladejo; Gonzalo Barón-Esquivias; José Luis Zamorano; Lourdes Betegón-Nicolás; Cristina Canal-Fontcuberta; Marina de Salas-Cansado; Darío Rubio-Rodríguez; Carlos Rubio-Terrés
Journal:  Aten Primaria       Date:  2016-01-30       Impact factor: 1.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.